⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27993664 | 0.71 | — | — | |
| SCHEMBL3402942 | 0.68 | — | — | |
| SCHEMBL18929765 | 0.65 | — | — | |
| SCHEMBL11540278 | 0.64 | — | — | |
| SCHEMBL31332023 | 0.64 | — | — | |
| SCHEMBL7332184 | 0.63 | — | — | |
| SCHEMBL386786 | 0.63 | — | — | |
| SCHEMBL7340145 | 0.63 | — | — | |
| SCHEMBL9435874 | 0.62 | — | — | |
| SCHEMBL14101244 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367229-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | MITOPOWER LLC (US) | 2025-12-04 | — | — | US | claimed |
| WO-2025003367-A1 | VITAMIN COMPOSITION FOR USE IN COSMETIC FORMULATIONS | CLARIANT INTERNATIONAL LTD (CH) | 2025-01-02 | — | — | WO | claimed |
| US-20240382512-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | MITOPOWER LLC | 2024-11-21 | — | — | US | claimed |
| EP-4313067-A1 | TREATMENT OF IMMUNE-RELATED DISORDERS, KIDNEY DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS, AND OXIDATIVE STRESS-ASSOCIATED DISORDERS USING NRH, NARH AND REDUCED DERIVATIVES THEREOF | Mitopower LLC (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230014055-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | MITOPOWER LLC | 2023-01-19 | — | — | US | claimed |
| WO-2022266322-A1 | TREATMENT OF IMMUNE-RELATED DISORDERS, KIDNEY DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS, AND OXIDATIVE STRESS-ASSOCIATED DISORDERS USING NRH, NARH AND REDUCED DERIVATIVES THEREOF | MITOPOWER LLC (US) | 2022-12-22 | — | — | WO | claimed |
| WO-2021098725-A1 | SYNTHETIC METHOD FOR NMN DERIVATIVE AND MEDICAL APPLICATIONS OF NMN AND ITS DERIVATIVE | TSINGHUA UNIVERSITY (CN) | 2021-05-27 | — | — | WO | claimed |
| EP-1214315-A1 | 1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF | Rephartox (NL) | 2002-06-19 | — | — | EP | claimed |
| WO-2001014370-A1 | 1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID ESTER DERIVATIVES AND METHOD FOR THE PREPARATION THEREOF | REPHARTOX (NL) | 2001-03-01 | — | — | WO | claimed |
| JP-56061354-A | — | — | None | — | — | JP | disclosed |
| US-20250367229-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | MITOPOWER LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367229-A1 | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof | MITOPOWER LLC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-3322419-B1 | SYNTHESES, ACTIVITIES, AND METHODS OF USE OF DIHYDRONICOTINAMIDE RIBOSIDE DERIVATIVES | UNIV CORNELL (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025003367-A1 | VITAMIN COMPOSITION FOR USE IN COSMETIC FORMULATIONS | CLARIANT INTERNATIONAL LTD (CH) | 2025-01-02 | — | — | WO | disclosed |
| US-5017566-A | Redox systems for brain-targeted drug delivery | UNIVERSITY OF FLORIDA (US) | 1991-05-21 | — | — | US | disclosed |
| US-5002935-A | Inclusion Complexing Hydroxypropylcyclodextrin with a Dihydropyridine-substituted Drug | UNIVERSITY OF FLORIDA (US) | 1991-03-26 | — | — | US | disclosed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | disclosed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | disclosed |
| EP-0327766-A2 | Redox systems for brain-targeted drug delivery | UNIVERSITY OF FLORIDA (US) | 1989-08-16 | — | — | EP | disclosed |
| JP-S5661354-A | NICOTINIC ACID DERIVATIVE | MITSUBISHI CHEM IND LTD | 1981-05-26 | — | — | JP | disclosed |